Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.39
-0.42 (-2.12%)
At close: May 8, 2026, 4:00 PM EDT
19.05
-0.34 (-1.75%)
After-hours: May 8, 2026, 5:54 PM EDT

Monte Rosa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
42.95123.6775.62---
Revenue Growth (YoY)
-73.07%63.54%----
Gross Profit
42.95123.6775.62---
Selling, General & Admin
37.8536.3835.1732.0427.3215.73
Research & Development
153.38141.5121.56111.2785.0657.16
Total Operating Expenses
191.23177.88156.73143.31112.3872.88
Operating Income
-148.28-54.21-81.11-143.31-112.38-72.88
Interest Income
15.0912.9410.579.333.760.05
Other Non-Operating Income (Expense)
1.31.540.42-0.780.12-1.12
Total Non-Operating Income (Expense)
16.414.4910.988.33.88-1.08
Pretax Income
-131.88-39.72-70.13-135.01-108.5-73.96
Provision for Income Taxes
-1.87-1.12.570.34--
Net Income
-130.01-38.63-72.7-135.35-108.5-73.96
Net Income to Common
-130.01-38.63-72.7-135.35-108.5-73.96
Shares Outstanding (Basic)
888374514725
Shares Outstanding (Diluted)
878374514725
Shares Change (YoY)
9.30%12.39%43.80%8.83%88.91%1548.09%
EPS (Basic)
-1.48-0.46-0.98-2.63-2.30-2.96
EPS (Diluted)
-1.48-0.46-0.98-2.63-2.30-2.96
Shares Outstanding
84.3265.5461.5150.1449.3246.54
Free Cash Flow
-19.66-27.538.01-62.84-105.38-69.1
Free Cash Flow Per Share
-0.23-0.330.51-1.22-2.23-2.76
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-345.21%-43.83%-107.26%---
Profit Margin
-302.69%-31.23%-96.14%---
FCF Margin
-45.76%-22.23%50.26%---
EBITDA
-139.94-45.85-72.99-137.09-108.64-70.75
EBITDA Margin
-325.80%-37.08%-96.52%---
EBIT
-148.28-54.21-81.11-143.31-112.38-72.88
EBIT Margin
-345.21%-43.83%-107.26%---
Effective Tax Rate
1.42%2.76%-3.66%-0.25%0.00%0.00%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q